thalidomide has been researched along with Uveitis in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Uveitis: Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study examined the outcomes of systemic or topical treatment with thalidomide, a compound that possesses anti-inflammatory, immunomodulatory and anti-angiogenic properties, in rats subjected to endotoxin-induced uveitis (EIU)." | 7.74 | Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. ( Calixto, JB; Di Giunta, G; Figueiredo, CP; Grumman, A; Medeiros, R; Passos, GF; Rodrigues, EB; Rodrigues, GB, 2007) |
| " Although corticosteroids are usually the first-line therapy for non-infectious uveitis, their long-term use is limited by potentially serious side effects in all possible delivery routes." | 5.56 | Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. ( Castro, BFM; Cenachi, SPF; Cotta, OAL; Fialho, SL; Guerra, MCA; Paiva, MRB; Silva, LM; Silva-Cunha, A; Vasconcelos-Santos, DV; Vieira, LC, 2020) |
| "Age and uveitis are related to conversion to biologics therapy." | 1.91 | Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment. ( Huang, D; Huang, W; Luo, L; Ren, F; Tang, L; Zhang, Z; Zhou, J, 2023) |
| " Although corticosteroids are usually the first-line therapy for non-infectious uveitis, their long-term use is limited by potentially serious side effects in all possible delivery routes." | 1.56 | Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. ( Castro, BFM; Cenachi, SPF; Cotta, OAL; Fialho, SL; Guerra, MCA; Paiva, MRB; Silva, LM; Silva-Cunha, A; Vasconcelos-Santos, DV; Vieira, LC, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 2 |
| Zhong, LQ | 1 |
| Li, WD | 1 |
| Wu, SJ | 1 |
| Song, HM | 1 |
| Zhou, J | 1 |
| Huang, W | 1 |
| Zhang, Z | 1 |
| Luo, L | 1 |
| Ren, F | 1 |
| Huang, D | 1 |
| Tang, L | 1 |
| Castro, BFM | 1 |
| Vieira, LC | 1 |
| Vasconcelos-Santos, DV | 1 |
| Cenachi, SPF | 1 |
| Cotta, OAL | 1 |
| Guerra, MCA | 1 |
| Paiva, MRB | 1 |
| Silva, LM | 1 |
| Silva-Cunha, A | 1 |
| Fialho, SL | 1 |
| Chen, Y | 1 |
| Li, Z | 1 |
| Li, H | 1 |
| Su, W | 1 |
| Xie, Y | 1 |
| Pan, Y | 1 |
| Chen, X | 1 |
| Liang, D | 1 |
| Hamuryudan, V | 1 |
| Hatemi, G | 1 |
| Tascilar, K | 1 |
| Sut, N | 1 |
| Ozyazgan, Y | 1 |
| Seyahi, E | 1 |
| Mat, C | 1 |
| Yurdakul, S | 1 |
| Yazici, H | 1 |
| Rodrigues, GB | 1 |
| Passos, GF | 1 |
| Di Giunta, G | 1 |
| Figueiredo, CP | 1 |
| Rodrigues, EB | 1 |
| Grumman, A | 1 |
| Medeiros, R | 1 |
| Calixto, JB | 1 |
| Torras, H | 1 |
| Lecha, M | 1 |
| Mascaró/, JM | 1 |
1 trial available for thalidomide and Uveitis
| Article | Year |
|---|---|
Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Behcet Syndrome; Colchicine; Drug Utilization; Follow- | 2010 |
6 other studies available for thalidomide and Uveitis
| Article | Year |
|---|---|
Thalidomide may be an effective drug for Blau syndrome: a case report.
Topics: Arthritis; Female; Humans; Nod2 Signaling Adaptor Protein; Sarcoidosis; Synovitis; Thalidomide; Uvei | 2022 |
Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Biological Factors; Biolo | 2023 |
Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Humans; Intravitreal Injections; Models, Ani | 2020 |
Apremilast Regulates the Teff/Treg Balance to Ameliorate Uveitis
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; CD4-Positive T-Lymphocytes; Disease Models, | 2020 |
Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Aqueous Humor; Blo | 2007 |
[Thalidomide in the treatment of aphthosis and Behçet's disease. 4 years' experience].
Topics: Adolescent; Adult; Aged; Behcet Syndrome; Drug Evaluation; Female; Humans; Male; Middle Aged; Necros | 1982 |